| Lai, Yongrong |
NCT06302491: A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia |
|
|
| Recruiting | 2 | 64 | RoW | AND017 capsules, AND017 Placebo | Kind Pharmaceuticals LLC | β -Thalassemia | 12/25 | 07/26 | | |
NCT06465550: A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major |
|
|
| Recruiting | 1 | 9 | RoW | BD211 | Shanghai BDgene Co., Ltd. | β-thalassemia | 12/26 | 12/26 | | |
| Enrolling by invitation | 1 | 10 | RoW | CS-101 | CorrectSequence Therapeutics Co., Ltd, First Affiliated Hospital of Guangxi Medical University | Beta-Thalassemia | 12/25 | 01/26 | | |
NCT06291961: A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major |
|
|
| Recruiting | 1 | 8 | RoW | CS-101 injection | CorrectSequence Therapeutics Co., Ltd | Beta-Thalassemia Major | 05/25 | 07/25 | | |
NCT06655662: Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients. |
|
|
| Recruiting | 1 | 8 | RoW | β-globin restored autologous hematopoietic stem cells | Shenzhen Hemogen | Β-thalassemia | 12/25 | 12/26 | | |
| Recruiting | 1 | 5 | RoW | CS-206 | CorrectSequence Therapeutics Co., Ltd, First Affiliated Hospital of Guangxi Medical University | Sickle Cell Disease | 12/26 | 06/27 | | |
NCT06772766: A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia |
|
|
| Recruiting | 1 | 40 | RoW | 9MW3011, 9MW3011 placebo | Mabwell (Shanghai) Bioscience Co., Ltd. | Beta-Thalassemia | 10/26 | 10/26 | | |
NCT06024876: A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia |
|
|
| Active, not recruiting | 1 | 5 | RoW | CS-101 | CorrectSequence Therapeutics Co., Ltd, First Affiliated Hospital of Guangxi Medical University | Beta-Thalassemia | 12/24 | 06/25 | | |
NCT05577312: Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia |
|
|
| Enrolling by invitation | 1 | 9 | RoW | BRL-101, BRL-101 autologous hematopoietic stem and progenitor cells injection | Bioray Laboratories, First Affiliated Hospital of Guangxi Medical University, Xiangya Hospital of Central South University, Chinese Academy of Medical Sciences, Nanfang Hospital, Southern Medical University | Beta-Thalassemia | 08/25 | 09/26 | | |
| Enrolling by invitation | N/A | 3 | RoW | BRL-101, Autologous hematopoietic stem and progenitor cells injection | Bioray Laboratories, First Affiliated Hospital of Guangxi Medical University | Sickle Cell Disease | 03/26 | 06/26 | | |
| Not yet recruiting | N/A | 45 | RoW | Assessments | Bioray Laboratories, First Affiliated Hospital of Guangxi Medical University, Xiangya Hospital of Central South University, Chinese Academy of Medical Sciences, Nanfang Hospital, Southern Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army, Shenzhen Children 's Hospital | Thalassemia, Beta | 08/38 | 10/38 | | |
NCT06685536: A Long-term Follow-up Study in Participants Who Received CS-101 |
|
|
| Enrolling by invitation | N/A | 5 | RoW | Safety and efficacy assessments | CorrectSequence Therapeutics Co., Ltd, First Affiliated Hospital of Guangxi Medical University | Beta-Thalassemia | 07/39 | 07/39 | | |
| Yu, Qitao |
OFFER, NCT04536558: Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study |
|
|
| Not yet recruiting | 3 | 352 | RoW | olanzapine plus fosaprepitant-based triple regimen, placebo plus fosaprepitant-based triple regimen | Sun Yat-sen University, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy | 02/21 | 03/21 | | |
ETER701, NCT04234607: A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 738 | RoW | TQB2450, Anlotinib, Etoposide, Carboplatin, TQB2450（blank）, Anlotinib（blank) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Extensive Small Cell Lung Cancer | 12/22 | 12/22 | | |
NCT06616532: PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 404 | RoW | PM8002, Paclitaxel, Topotecan | Biotheus Inc. | SCLC | 01/27 | 12/28 | | |
NCT04398940: A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 71 | RoW | TQ-B3139 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 01/22 | 10/22 | | |
| Recruiting | 2 | 270 | RoW | TQB2102 for injection, TQB2102 for injection combined with Benmelstobart injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Non-Small Cell Lung Cancer | 10/25 | 02/26 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 183 | Japan, US, RoW | Glumetinib, SCC244 | Haihe Biopharma Co., Ltd. | C-Met Exon 14 Mutation | 10/23 | 12/23 | | |
NCT04284488: Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors |
|
|
| Recruiting | 1/2 | 104 | RoW | APG-1387 for Injection, Toripalimab, JS001 | Ascentage Pharma Group Inc. | Advanced Solid Tumor | 04/24 | 04/24 | | |
NCT06500676: A Study of GFH375 in Patients with Advanced Solid Tumors with KRAS G12D Mutations |
|
|
| Recruiting | 1/2 | 290 | RoW | GFH375 | Genfleet Therapeutics (Shanghai) Inc. | KRAS G12D Mutations, Advanced Solid Tumors | 07/28 | 12/28 | | |
NCT06050980: Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation |
|
|
| Recruiting | 1 | 220 | RoW | HSK40118 | Haisco Pharmaceutical Group Co., Ltd. | NSCLC | 08/25 | 06/27 | | |
